CJC-1295 W/ DAC

CJC-1295 with DAC is a synthetic analog of growth hormone–releasing hormone (GHRH) designed to provide long-lasting stimulation of growth hormone (GH) secretion. The peptide contains amino acid modifications that improve stability, plus a Drug Affinity Complex (DAC) that binds to albumin in the bloodstream. This extends its half-life from about 30 minutes to nearly a week, allowing once-weekly or biweekly dosing.

CJC-1295 activates GHRH receptors on pituitary cells, triggering a sustained rise in GH and insulin-like growth factor 1 (IGF-1). Clinical studies show GH levels can increase 2–10 fold and IGF-1 levels rise 1.5–3 fold, with effects lasting up to 11 days after a single dose. Unlike natural GHRH, which works in short pulses, CJC-1295 provides continuous stimulation, supporting muscle growth, tissue repair, metabolism, and recovery.

Sustained GH Elevation: Prolonged rise in plasma GH lasting 6+ days (Human Study)
Prolonged IGF-1 Stimulation: IGF-1 elevated for 9–11 days (Human Study)
Convenient Dosing: Effective with weekly or biweekly administration (Human Study)
Cumulative Effects: IGF-1 levels can remain above baseline for up to 28 days (Human Study)
Lean Muscle Support: May enhance protein synthesis and muscle repair (Human Study)
Fat Metabolism: May increase fat oxidation and improve metabolic rate (Human Study)
Recovery Support: Promotes collagen formation and tissue remodeling (Human Study)
Sleep and Cognition: Potential improvements in sleep quality and mental clarity (Human Study)
Cellular Regeneration: Possible benefits for skin, metabolism, and healthy aging (Human Study)
Tolerability: Generally well tolerated at therapeutic doses (Human Study)

Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
Ionescu M, et al. Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults. Clin Endocrinol. 2006;64(2):187-194. PMID:16352683
Teichman SL, et al. Pharmacokinetic and pharmacodynamic properties of CJC-1295, a long-acting growth hormone-releasing hormone analog. Drug Dev Res. 2005;66(4):248-256. doi:10.1002/ddr.20089
Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29–albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
Fazeli PK, et al. Safety and efficacy of CJC-1295 in healthy volunteers: a phase I clinical trial. J Clin Invest. 2006;116(6):1561-1570. doi:10.1172/JCI27849

$75.00

Per Unit

In stock